Alterations in DNA methylation patterns are one of the earliest and most common events in tumorigenesis. Overall levels of genomic methylation often decrease during transformation, but localized regions of increased methylation have been observed in the same tumors. We have examined changes in the methylation status of the muscle determination gene myoD, which contains a CpG island, as a function of oncogenic transformation. This CpG island underwent de novo methylation during immortalization of 10T1/2 cells, and progressively more sites became methylated during the subsequent transformation of the cells to oncogenicity. The greatest increase in methylation occurred in the middle of the CpG island in exon 1 during transformation.
Interestingly, no methylation was apparent in the putative promoter of myoD in either the 1OT1/2 cell line or its transformed derivative. The large number of sites in the CpG island that became methylated during transformation was correlated with heterochromatinization of myoD as evidenced by a decreased sensitivity to cleavage of DNA in nuclei by MspI. A site in the putative promoter also became insensitive to MspI digestion in nuclei, suggesting that the chromatin structural changes extended beyond the areas of de novo methylation. Unlike Lyonized genes on the inactive X chromosome, whose timing of replication is shifted to late S phase, myoD replicated early in S phase in the transformed cell line. Methylation analysis of myoD in DNAs from several human tumors, which presumably do not express the gene, showed that hypermethylation also frequently occurs during carcinogenesis in vivo. Thus, the progressive increase in methylation of myoD during immortalization and transformation coinciding with a change in chromatin structure, as illustrated by the in vitro tumorigenic model, may represent a common mechanism in carcinogenesis for permanently silencing the expression of genes which can influence cell growth and differentiation.
Oncogenic transformation is often associated with a failure of cells to differentiate to end-stage phenotypes in an appropriate fashion. During tumorigenesis, the pattern and overall level of DNA methylation is altered, with hypomethylation of the genome being an early and common epigenetic modification associated with carcinogenesis (see reference 23 for a review). Despite the overall decrease in methylation, some areas of DNA, including some CpG islands associated with genes, become hypermethylated in tumor cell lines (5, 13) and uncultured tumors (4) . These changes in methylation patterns may cause significant changes in the control of gene expression during tumorigenesis. Changes in tnethylation and heterochromatinization of CpG island-containing genes have been suggested as a mechanism of permanently silencing the expression of nonessential genes during the establishment of immortal cell lines (1, 25) . In this study we examined the methylation status, heterochromatinization, and timing of replication of the myoD muscle determination gene for changes resulting from oncogenic transformation.
The 1OT1/2 cell system was originally developed by Rezni-koff and her colleagues for in vitro studies on chemical carcinogenesis (34, 35) . These immortalized cells can be transformed to oncogenicity by treatment with chemical carcinogens (34) or can be induced to undergo myogenesis by treatment with the nucleoside analog 5-azacytidine (11, 43) .
Myoblast conversion is associated with the activation of the muscle determination gene myoD (12) . Whether activated by 5-azacytidine or introduced in expression vectors, myoD converts 10T1/2 cells to functional myoblasts which proliferate until reaching confluence and then differentiate into myotubes. Thus, the expression of myoD alone is insufficient to terminate cellular proliferation. However, determined myoblasts derived from 1OT1/2 cells are resistant to chemically induced carcinogenesis, although they can still become oncogenic following transfection with an activated oncogene (20) . The tumorigenicity of an oncogenic 1OT1/2 derivative is also not affected by endogenous or transfected myoD expression (22) . Thus, the precise relationship of myoD expression to cellular proliferation and oncogenicity is unclear despite its dramatic ability to induce differentiation.
We have previously shown that in the myoD gene the CpG island, which is not methylated in normal mouse tissues, becomes de novo methylated during the establishment of cell lines and is further methylated after transformation by chemical carcinogens (23, 24) . We have also shown that in oncogenically transformed cells, the gene is more resistant to activation by 5-azacytidine and to autoactivation by a transfected myoD expression vector (22, 43) .
The purpose of the present experiments was to extend the methylation studies to include the putative myoD promoter and an upstream enhancer element and to determine whether changes in chromatin structure accompanied the process of transformation. In particular, we were interested in determining whether the increased methylation of the CpG island might be associated with heterochromatinization, resulting in increased resistance to nuclease digestion and to a change in timing of replication for myoD. We also wanted to determine whether these methylation changes were exclusive to in vitro carcinogenesis by examining the methylation status of myoD in several types of human tumors. Restriction digests were electrophoresed on 1% agarose gels in lx TAE (36) and alkali blotted to nylon membranes (Zetaprobe; Bio-Rad, Richmond, Calif.) according to the manufacturer's protocol. The blots were hybridized (10) to 200 ng of 32P-labeled probe (16) . All digests and Southern blots were done two or three times to ensure that the results observed were not due to incomplete digestions.
MATERIALS AND METHODS
Ligation-mediated PCR genomic sequencing. Ligation-mediated PCR genomic sequencing (32, 33) was performed on 10T1/2, MCA, and plasmid DNAs as previously described (25) . The primers for analysis of the promoter were as follows: first primer, Myol2-1 (5'-GTG,GTG,AAG,AAA,GCA,GTC-3'); second primer (for PCR), Myol2-2 (5'-AAG,AAA,GCA,G TC,GTG,TCC,TGG,GGC,G-3'); and third primer (for labeling), Myol2-3 (5'-AAA,GCA,GTC,GTG,TCC,TGG,GGC, GTC,CTG-3').
PCR of enhancer. (5'-CCT,TGC,TCT,CTT,   GAT,CCT,CTC,TTG,C-3') and MyoE4 (5'-GCC,CAG,CCA,   CCA,GGA,TGG,TAT, [pH 7.9 ], 0.6 M NaCl, 1% sodium dodecyl sulfate, and 10 mM EDTA) containing 400 mg of proteinase K per ml was then added, and the mixtures were incubated at 37°C for 2 h. Samples were extracted once with phenol-chloroform and twice with chloroform-isoamyl alcohol. DNA was ethanol precipitated and resuspended in TE (10 mM Tris-HCl, 1 mM EDTA). This DNA was then treated with Stul (Boehringer Mannheim Biochemicals) for 16 h with 4 U of enzyme per ,ug of DNA and then with an additional 1 U of enzyme per ,ug of DNA for 4 h. Temperature and buffer were as recommended by the manufacturer. Samples were then electrophoresed, Southern blotted, and probed as described above. A 0.48-kb MspI fragment of the myoD cDNA (12) (the exon sequences between MspI sites 6 to 8 in Fig. 1 ) was used to probe the MspI nuclease sensitivity blots. A 180-bp fragment of the myoD cDNA downstream from MspI site 9 was used to probe the PstI nuclease sensitivity blots.
Timing of replication. The timing-of-replication experiments were performed according to the method of Hansen et al. (19) , with minor modifications in preparation of the cell suspension for flow sorting. Log-phase cultures of 1OT1/2 and MCA cells (3 x 106 cells per 150-mm-diameter dish) were treated with 50 ,uM bromodeoxyuridine (BUdR) for 90 min. The cells were then trypsinized, pelleted, resuspended in 5 ml of PBS plus 5 mM EDTA (PBS-EDTA) at 4°C, and pelleted again. The pellets were resuspended in 1 ml of PBS-EDTA and vortexed, 3 ml of ice-cold 95% ethanol was added dropwise with constant vortexing, and the mixture was then incubated for 16 h at 4°C for fixation. The fixed cells were stepped out of the 70% ethanol by successive resuspensions in ice-cold 50%, 25%, and 10% ethanol and two resuspensions in PBS-EDTA, ending in a final volume of 3 ml. RNase A was added to a final concentration of 20 ,ug/ml and propidium iodide was added to 50 ,uglml, and the samples were incubated at room temperature for 30 min before cell sorting. Cell sorting was done on a FacsStar (Becton-Dickinson) according to DNA content, and subsequent DNA immunoprecipitation and isolation were done as described previously (19) , with BUdR-labeled HeLa DNA used to spike the samples as a control for BUdR-labeled DNA recovery.
Immunoprecipitated DNA from 2,000 cells of each cell cycle The samples were then electrophoresed, blotted, and probed with the 32P-end-labeled oligonucleotide Vh-3 (5'-TCC,TGC,AAG,GCT,TCT,GGC-3') as described above. As a control for BrdU-labeled DNA recovery from the immunoprecipitation, primers J0285 (5'-CCG, GAA,GTT,ACT,CTA,GTC,TA-3') and J0286 (5'-TTA,TAA, TGC,CGG,TCA,ACC,TT-3') were used to amplify the human D9S63 locus from the HeLa DNA used to spike the cell cycle fractions. The PCR was done for 30 cycles of 94°C for 1 min, 52°C for 40 s, and 72°C for 1 min. These samples were then Southern blotted and probed with a 32P-end-labeled GT oligonucleotide (5'-GTG,TGT,GTG,TGT,GTG,TGT,GTG-3').
RESULTS
The 1OT1/2 mouse embryonic fibroblast line, developed for studies on chemical carcinogenesis (34, 35) , and NCA, a tumorigenic cell line derived from 1OT1/2 cells by treatment with 3-methylcholanthrene (22, 34) , were used for this work.
Unlike the parental 1OT1/2 cells, MCA cells do not growtharrest when they become confluent in tissue culture, and they form fibrosarcomas when injected into immunosuppressed or immunodeficient mice. This cell system provides an opportunity to study changes in DNA methylation, chromatin structure, and replication timing associated with immortalization and subsequent oncogenic transformation.
CpG islands are regions of DNA approximately 0.5 to 2 kb in length that contain the dinucleotide at close to its expected frequency. In contrast, the occurrence of the dinucleotide in the bulk of the genome is found at 20% of its expected frequency (18) . CpG islands are generally associated with genes and remain mostly unmethylated in all vertebrate tissues. Notable exceptions are the methylation of CpG islands on the inactive X chromosome in females (28, 44) and the methylation of CpG islands of imprinted genes on autosomes like the paternal H19 gene (17) or the maternal insulin-like growth factor 2 (Igf2) receptor (40) .
We have previously published data on the appearance of de novo cytosine methylation in the CpG island of the mouse myoD gene in 1OT1/2 and MCA cells (25) . Those earlier results and results reported in this paper are summarized in Fig. 1 , which shows the CpG dinucleotide distribution in myoD. The CpG island spans the first exon of the gene and extends a short distance both 5' and 3' from the first exon. Figure 1 also shows the position of MspI restriction endonuclease sites whose methylation status and sensitivities to nuclease digestion in nuclei were studied in previous and the present work. Additional restriction endonuclease sites examined for methylation status or nuclease sensitivity are individually labeled. The data shown for 1OT1/2 and MCA cells illustrate both the level of methylation of CpG sites, examined by restriction endonuclease digestion or ligation-mediated PCR genomic sequencing, and the nuclease sensitivity of myoD in nuclei.
The methylation status of CpG sites in and upstream of the putative promoter region, which extends -250 bp from the transcription start site (41, 46) , was examined. Several restriction enzymes sensitive to cytosine methylation were used to study the level of methylation at sites further upstream from the transcriptional start site. First, two BstUI sites (recognition sequence, CGCG) located approximately -200 and -150 bp from the transcription start site (B1 and B2, respectively, in Fig. 1 ) were examined. The DNAs were digested with HindIII and BstUI, electrophoresed, alkali blotted, and probed with the HindIII-Smal fragment of myoD (Fig. 2) . Control digests of DNAs isolated from 1OT1/2 and MCA cells with HindIll alone showed the expected 2.6-kb band. Double digestion of 1OT1/2 DNA with BstUI and HindIlI resulted in the cutting of the 2.6-kb band, yielding bands of 450 and 400 bp in length, corresponding to digestion at BstUI sites B2 and Bi, respectively. The presence of these two bands in the double digest indicated that site Bi was partially methylated and that site B2 was unmethylated. The double digest of MCA cell DNA showed the 450-bp band and a weak band at 2.6 kb. The absence of the 400-bp band showed that MCA cell DNA was fully methylated at site B1 and mostly unmethylated at site B2. The presence of a weak band at 2.6 kb suggested some partial methylation of both BstUI sites in a small percentage of myoD alleles in the MCA cells. Therefore, a significant increase in methylation was seen at site Bi in MCA DNA compared with that in 1OT1/2 DNA, while at site B2, which is closer to the transcription start site, both cell lines were predominately unmethylated.
The methylation of MspI sites 1 and 2 (recognition sequence, CCGG) and HhaI sites HI and H2 (recognition sequence, GCGC), all upstream from the transcriptional start site (Fig.  1) , was next examined for both cell types (Fig. 3) (Hi and H2) , BstUI sites (Bi and B2), StuI sites (Si and S2), and PstI sites (P1, P2, and P3) shown on the same line. These restriction sites were used in methylation analyses or nuclease sensitivity studies. The filled box marks the HindIII-SmaI fragment used as the probe in methylation studies of sites in the putative promoter of myoD. The bottom two lines summarize the results for 10TI/2 and MCA cells from previous studies (25) and studies presented in this paper. Circles mark the CpG sites analyzed for methylation either by ligation-mediated PCR genomic sequencing or by restriction digestion and Southern analysis. Open circles represent no methylation, filled circles represent complete methylation, and quarter-filled, half-filled, and three-quarter-filled circles represent increasing amounts of partial methylation at the CpG sites marked. Upward-pointing arrows mark the restriction sites in myoD in nuclei from 1OT1/2 and MCA cells which are accessible to nucleases, with the longer arrow indicating a greater degree of digestion at site P3.
since the 1.6-kb band was partially digested to 320 bp and the 420-bp band was completely digested to 210 bp. In MCA cells, site H2 remained unmethylated, whereas site Hi became completely methylated as indicated by the absence of the 320 bp band. This was the only obvious methylation difference between the two cell lines at the HpaII and HhaI sites examined as shown in Fig. 3 .
A study of seven CpG sites near MspI site 2 in the putative promoter of myoD was performed by ligation-mediated PCR genomic sequencing. The results of these experiments (data not shown) also showed no evidence of methylation around MspI site 2 in 1OT1/2 and MCA DNAs (Fig. 1) . The ligationmediated PCR results suggested that the observation of unmethylated specific restriction sites in the promoter, as discussed above, reflected the overall methylation status of CpG sites in the promoter region. Thus, the promoter and 5' end of the CpG island remained unmethylated during the establishment of the 1OT1/2 cell line and during its subsequent transformation to oncogenicity. Since the myoD CpG island and the flanking sites examined here were not methylated in DNA from normal mouse tissues (22a, 24), the changes in methylation seen in 1OT1/2 and MCA DNAs were probably the result of de novo methylation events associated with immortalization and transformation.
Methylation analysis of a putative myc-binding site in an enhancer region (41) 5,500 bases upstream from the transcriptional start site of myoD was done by using PCR (Fig. 4) to determine whether this distal regulatory region underwent similar methylation changes. Prior to PCR amplification with primers that flank a CpG site within the myc-binding consensus sequence (CACGTG) (6), DNA was digested with an enzyme that cut outside the amplified region (MspI) or with an enzyme that cut at the myc-binding site (either BbrPI [methylation insensitive] or MaeII [methylation sensitive]). PCR products were visible only in the MspI digestions, which indicated that the site was unmethylated in both cell lines since both BbrPI and MaeII cleaved the DNA. Therefore, although located in a region depleted of CpGs (two CpGs in 500 bp), this site showed no methylation in either cell line.
Nuclease sensitivity of myoD. Antequera and colleagues (2) showed that MspI sites, in which the internal cytosine residue of the recognition site was methylated, became resistant to enzymatic cleavage in nuclei. Since MspI is not inhibited by methylation at the internal cytosine in naked DNA, the nuclease insensitivity observed in nuclei was presumably due to the binding of methylated DNA-binding proteins at those sites, preventing digestion by MspI. We examined whether similar alterations in nuclease sensitivity at myoD had accompanied the increasing DNA methylation in the two cell lines.
Nuclei from 1OT1/2 and MCA cells were incubated with increasing concentrations of MspI. DNA was extracted, cut with Stul, electrophoresed, blotted, and probed with a fragment of the myoD cDNA (Fig. 5) . DNA from 1OT1/2 nuclei digested with 50 to 200 U of MspI per ml showed bands of 630, 470, and 350 bp, corresponding to cutting at MspI sites 2, 7, and 5, respectively, which were not present at lower nuclease concentrations. In contrast, myoD in MCA nuclei was much more resistant to MspI cleavage than that in 1OT1/2 cells, since no cutting at MspI sites 2, 5, or 7 was detected even at the highest enzyme concentration (200 U/ml) (Fig. 5B) (7) . We also examined the nuclease sensitivity of myoD in normal mouse liver nuclei (Fig. 5C ) to compare the chromatin structure of myoD in 1OT1/2 and MCA cells with the chromatin structure of a normal cell type that also does not express myoD (12) . The liver nucleus blot showed bands indicating cutting at Mspl sites 2, 5, and 7 that were clearly visible at Mspl concentrations of 100 and 200 U/ml. Thus, the chromatin structure at these sites in 1OT1/2 cells closely resembled that found in normal liver tissue and indicated that the heterochromatinization seen in MCA cells was tightly correlated with the substantial increase of DNA methylation in the CpG island of myoD.
The sensitivities of the three Pstl sites (Fig. 1) obtained for 1OT1/2 cells (data not shown). Site P3 was slightly more susceptible to cleavage than site P2, since a band of 550 bp appeared at an enzyme concentration of 10 U/ml, whereas a band of 500 bp, corresponding to cleavage of site P2, appeared at 50 U/ml. Similar experiments to test the accessibility of site P1 showed no cleavage in either cell type at enzyme levels of 100 U/ml (data not shown). The results of the analyses, shown in Fig. 1 , suggested that the region of nuclease inaccessibility in MCA cells extended throughout the CpG island but was not manifested in the 3' region of the gene. Timing of myoD replication in S phase. CpG islands on the inactive X chromosome in female mammals are more methylated and replicate later than their active counterparts and undergo changes in chromatin structure (38) . Since the myoD CpG island had undergone both de novo methylation and chromatin structural changes during transformation, we next determined whether these changes had altered the timing of replication of myoD during S phase. This was determined by using log-phase, unsynchronized cultures of 1OT1/2 and MCA cells; the cells were incubated for 90 min with BUdR to label newly replicated DNA, and then single-cell suspensions were prepared and fixed. The cells were then sorted according to DNA content and fractionated into G1, SI, S2, S3, S4, and G2/M samples (19) . DNA was isolated from the cell cycle fractions, immunoprecipitated with anti-BUdR, and used as a PCR template for quantitating the newly replicated DNA. In two separate experiments, both 1OT1/2 and MCA cells showed a peak of myoD replication in the early S-phase fraction, S2 (Fig.  7) . In comparison, replication of Ig-Vh peaked in fraction S3 (Fig. 7) and continued into the G2 fraction in both cell lines. This was consistent with a report of Ig-Vh replication occurring in late S phase in 1OT1/2 cells (14) . Thus, transformation to oncogenicity of the 1OT1/2 cells did not result in complete Lyonization of the autosomal gene myoD, since hypermethylation and heterochromatinization had occurred without a shift to replication in late S phase.
Methylation of myoD in human tumors. The methylation status of the human myoD gene (MyJ3 [8] 
DISCUSSION
Our results show that abnormal methylation of the myoD CpG island was initiated during immortalization and greatly increased during subsequent transformation by a chemical carcinogen. This hypermethylation that occurred during oncogenesis was associated with significant changes in chromatin structure but did not alter the timing of myoD replication in S phase.
While the significance of myoD in the process of transformation to oncogenicity is obscure, the changes in the CpG island that occurred during carcinogenesis were dramatic. The progressive increase in methylation and heterochromatinization mimicked two features of the Lyonization of genes on the X chromosome. Lyonization occurs during X inactivation and permanently silences expression of the inactivated genes (28, 44) . The similarities between Lyonization and the changes in the myoD CpG island during transformation might reflect a common, heritable means of inactivating nonessential genes.
Abnormal methylation of myoD was initiated during the establishment and immortalization of the embryonic fibroblast cell line 1OT1/2, in which the methylation spread in towards the normally unmethylated myoD CpG island while the center of the island in exon 1 remained largely unmethylated. During the 3-methylcholanthrene-induced carcinogenesis of 1OT1/2 cells to MCA cells, the methylation increased and progressed into the middle of the CpG island (Fig. 1) . Increased methylation of myoD during transformation seems to be a frequent event in 1OT1/2 cells, since we previously observed it in three other cell lines derived by treatment with 3-methylcholanthrene or bleomycin (25) . Interestingly, several sites in the promoter of myoD (B2, H2, MspI site 2, and six other CpG sites [ Fig. 1]) were protected from being methylated during either immortalization or oncogenesis.
myoD is located on mouse chromosome 7, as is the parentally imprinted Igf2 gene, which also underwent heterochromatinization (37) and hypermethylation (15) of normally unmethylated sites during the oncogenic transformation of 1OT1/2 cells. Indeed, both the increase in methylation and the decrease in sensitivity to MspI digestion in nuclei observed at the Igf2 locus in MCA cells, compared with those in 1OT1/2 cells, are remarkably similar to the alterations seen at myoD. Several genes on human chromosome 11p, which is syntenic to mouse chromosome 7, have also shown similar methylation changes resulting from immortalization in vitro and tumorigenesis in vivo (e.g., in the calcitonin gene [4, 5] ). Thus, the increases in methylation of the myoD CpG island in MCA cells may be indicative of a host of methylation changes on these syntenic chromosomes in both mice and humans during tumorigenesis.
The increase in methylation of myoD in MCA cells was accompanied by a corresponding decrease in sensitivity to nucleases for DNA in nuclei, which could indicate that the chromatin was also less accessible to transcription factors and thereby was transcriptionally repressed. CpG islands that are sensitive to nuclease digestion in nuclei have been shown to be transcriptionally competent, while those that are insensitive are repressed (45) . The increased resistance of myoD in MCA nuclei to digestion by MspI (Fig. 5B) spanned the entire CpG island and included MspI site 2, which had remained unmethylated throughout immortalization and transformation. Thus, it seems unlikely that cytosine methylation within the promoter region plays a direct role in the heterochromatinization of the promoter, which was more than fourfold less sensitive to nucleases in MCA nuclei than in 1OT1/2 nuclei. Since the change in chromatin structure at this site in MCA cells is methylation independent, heterochromatinization may contribute to the observed resistance of myoD in MCA cells to activation by the demethylating reagent 5-azacytidine and to autoactivation by transfection with myoD expression vectors (22) pression of myoD in 1OT1/2 cells in obscure, the refractivity of the gene to activation in MCA cells seems easier to understand. Bird and colleagues (2, 7, 29, 30) have shown that the methylation of CpG islands can repress transcription by an indirect mechanism involving the presumed participation of methylated DNA-binding proteins, which prevent transcription. The extensive methylation of CpG sites in the vicinities of MspI sites 6, 7, and 8 in MCA cells may lead to enhanced binding of such proteins, which could induce the heterochromatinization of the gene. The heterochromatinization of myoD may also involve the incorporation of histone Hi into local nucleosomes, since histone Hi has been associated with both transcriptionally inactive chromatin (26) and regions of DNA containing methylcytosine (3). Our results imply that this heterochromatinization can extend into flanking unmethylated regions, since the nuclease sensitivity of site 2 was decreased although it remained unmethylated (Fig. 5) . This provides an endogenous example of the spreading of heterochromatin beyond the core of increased methylation (around MspI site 6 in MCA cells [ Fig. 1]) and agrees with the observations of Kass et al. (27) . They reported that exogenous plasmid sequences containing methylated patches were introduced into mouse fibroblasts and subsequently exhibited heterochromatin formation that extended beyond the methylated patches.
The hypermethylation and heterochromatinization of the myoD CpG island were similar to the Lyonization of X inactivated genes. However, unlike the case for Lyonized genes on the inactive X chromosome, the timing of replication of myoD in early S phase in 1OT1/2 cells was unaltered in MCA cells (Fig. 7) . Therefore, only two of the three characteristic aspects of Lyonization, i.e., hypermethylation and heterochromatinization, occurred at the myoD gene as a result of transformation to oncogenicity. Results for the Igf2 gene have also shown that increases in methylation and heterochromatinization occurred during the oncogenic transformation of 1OT1/2 cells into MCA cells (15, 37) , and similarly, there was no a. Our experiments have also shown that the human myoD homolog, Myf3, is hypermethylated in both cultured and uncultured human tumors, with the exception of rhabdomyosarcomas. Thus, methylation of this CpG island is a common event in human carcinogenesis as well. We and others previously showed that most rhabdomyosarcomas express Myf3 (21, 39) and thus have overcome the possible growth-suppressive effects of myoD-induced differentiation, probably because of the absence of a factor necessary for Myf3 function (42) . Therefore, it is probably unnecessary for hypermethylation of myoD to occur in rhabdomyosarcomas in order to prevent any potential growth-retarding consequences of myoD expression.
We have shown that hypermethylation of the myoD CpG island is a common feature of oncogenic transformation both in vitro and in vivo. The increase in methylation in vitro was accompanied by a corresponding decrease in sensitivity to nucleases for DNA in chromatin, which may indicate that the chromatin was less accessible to transcription factors as well and therefore was transcriptionally incompetent. This extends the observations of Baylin et al. (4) that other CpG islands on human chromosome lip serve as sites for de novo methylation in human tumors. This progressive increase in methylation accompanied by heterochromatinization of nonessential genes might therefore be a common occurrence in tumor cells, providing a somatically heritable silencing of genes relevant to growth control and differentiation. The widespread occurrence of aberrant methylation of CpG islands in transformed cells (4, 23) suggests that these events may be common during transformation and may therefore be important in the transformation process itself. ACKNOWLEDGMENT This work was supported by grant CA 49758 from the National Cancer Institute.
